Fors M, Dupuy J, Viada C. Effectiveness of adaptive designs for phase II cancer trials. Contem. Clin. Trials. 2012 Ene; 33 (1): 223-7.

Luaces P, Lazo NG, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YÁ, Moreno BP, Alvarez ES, Callejo IP, Alert J, Martell JA, Gonzalez YS, Gonzalez YS, Astudillo de la Vega H, Ruiz-Garcia EB, Ramos TC. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther. 2012 Jun;13(8):600-5

Torre A, Hernández J, Ortiz R, Cepeda M, Pérez K, Car A, Viada C, Toledo D, Guerra PP, García E, et al. NGlycolylGM3/VSSP Vaccine in Metastatic Breast Cancer Patients: Results of Phase I/IIa Clinical Trial. Breast Cancer 2012:6 151–157

Volver a publicaciones

Páginas: 1 2 3